Dissecting innate immune determinants of severity and resolution in a longitudinal study of COVID-19
Lead Research Organisation:
University of Glasgow
Department Name: College of Medical, Veterinary, Life Sci
Abstract
The knowledge gap in COVID-19. Myeloid cells have a fundamental role in immune protection against infection. However, their powerful activity against pathogens is usually tightly regulated. This is because when this homeostatic control is deregulated, the over-activated myeloid cells can damage tissues, e.g. resulting in inflammatory joint diseases. Data emerging from the first wave of SARS-CoV-2 infection suggest that the catastrophic tissue damage following coronavirus infection can be attributed to over-activation of myeloid cells, resulting in hospitalisation with respiratory insufficiency and severe COVID-19. There is an urgent need for additional therapeutics to attenuate this progression of severity. With this project, we propose to address important and as-yet unanswered questions about the role of myeloid cells in severe COVID-19. These include: (i) Can we identify characteristics of myeloid cells at an early stage of SARS-CoV-2 infection that might help predict the clinical course of disease? (ii) What allows myeloid cells to escape the homeostatic regulation that would normally attenuate pathology? (iii) Can the regulatory mechanisms be reinstated? (iv) Do myeloid cells retain their aberrant activated state (epigenetics) and contribute to long-term post-COVID-19 symptoms (long-COVID-19)?
Experimental plan. To address this knowledge gap, we will investigate the changes in myeloid cells in COVID-19 patients from the day of admission to hospital to post-COVID-19 phase at single cell resolution. Our specific plans include (i) investigating transient changes in their molecular pathways, particularly regulatory mechanisms that should switch-off activation. We will also explore (ii) whether SARS-CoV-2 infection induces long-lasting memory of aberrant activation (epigenetics) in myeloid cells and whether this contributes to long-COVID-19 pathologies.
Expectation. We anticipate that our expertise in myeloid cell biology, experienced clinical monitoring and new technologies will discover new mechanisms by which myeloid cells contribute to progression or resolution of COVID-19 disease. From that knowledge we will identify myeloid cell characteristics (biomarkers) that can predict risk of developing severe and/or long COVID-19 and therapeutic targets for new drugs to prevent over-activation of myeloid cells during SARS-CoV-2 infection. The therapeutic potential of these discoveries will be tested in SARS-CoV-2 infected human lung 2D and 3D models in the laboratory.
Team. To tackle these challenges, we gathered an international research team of scientists and clinicians with diverse and complementary expertise. These include expertise and facilities in: myeloid cell pathologies (Research into Inflammatory Arthritis Centre Versus Arthritis, RACE, University of Glasgow), COVID-19 (COVID-19 Academic Hospital, Fondazione Gemelli IRCCS, Rome, Italy), SARS-CoV-2 (Centre of Virus Research, University of Glasgow) and epigenetics (Institute of Cancer Sciences, University of Glasgow).
Experimental plan. To address this knowledge gap, we will investigate the changes in myeloid cells in COVID-19 patients from the day of admission to hospital to post-COVID-19 phase at single cell resolution. Our specific plans include (i) investigating transient changes in their molecular pathways, particularly regulatory mechanisms that should switch-off activation. We will also explore (ii) whether SARS-CoV-2 infection induces long-lasting memory of aberrant activation (epigenetics) in myeloid cells and whether this contributes to long-COVID-19 pathologies.
Expectation. We anticipate that our expertise in myeloid cell biology, experienced clinical monitoring and new technologies will discover new mechanisms by which myeloid cells contribute to progression or resolution of COVID-19 disease. From that knowledge we will identify myeloid cell characteristics (biomarkers) that can predict risk of developing severe and/or long COVID-19 and therapeutic targets for new drugs to prevent over-activation of myeloid cells during SARS-CoV-2 infection. The therapeutic potential of these discoveries will be tested in SARS-CoV-2 infected human lung 2D and 3D models in the laboratory.
Team. To tackle these challenges, we gathered an international research team of scientists and clinicians with diverse and complementary expertise. These include expertise and facilities in: myeloid cell pathologies (Research into Inflammatory Arthritis Centre Versus Arthritis, RACE, University of Glasgow), COVID-19 (COVID-19 Academic Hospital, Fondazione Gemelli IRCCS, Rome, Italy), SARS-CoV-2 (Centre of Virus Research, University of Glasgow) and epigenetics (Institute of Cancer Sciences, University of Glasgow).
Technical Summary
The knowledge gap in COVID-19. The clinical, social and economic disruption caused by SARS-CoV-2 infection and its unpredictable progression to Acute Respiratory Distress Syndrome (ARDS) and chronic poor-health represents a global public health emergency. Emerging COVID-19 studies attribute pathogenesis to immune dysregulation, particularly implicating innate immunity to host tissue disruption. Severe lung pathology is associated with an aberrant inflammatory hyper-cytokine response, predominantly from myeloid cells (monocytes/macrophages). Age, gender, BMI and underlying medical conditions are risk factors, but there is a knowledge gap of host mechanisms that fail to restrain this aberrant response in acute-severe and long-term disease as compared with milder resolving disease. Our hypothesis is that myeloid cells from patients with severe and chronic COVID-19 have impaired endogenous homeostatic mechanisms that limit the pathogenic monocyte and lung macrophage activation in milder forms of disease.
Study protocol: (i) Longitudinal study of matched blood and lung lavage myeloid cells during the disease trajectories of moderate compared with severe COVID-19 with long-lasting ill-health. Single-cell phenotyping (transcriptome/proteome) will identify innate immune mechanisms determining acute and long-term pathogenesis and resolution. (ii) Ontogeny trajectory modelling of paired blood and lung lavage myeloid cells, in conjunction with epigenetic mapping (scATACseq) of identified pathways, will pinpoint monocyte drivers and biomarkers of acute and long-term pathogenic or resolving lung responses. (iii) An in vitro 2D and 3D model of human lung cell infection with SARS-CoV-2 will test the therapeutic potential of pathogenic and resolving pathways identified above.
Deliverables: Predicative myeloid biomarkers of acute and long-term COVID-19 severity, and therapeutic targets that could restrain aberrant pathogenic responses.
Study protocol: (i) Longitudinal study of matched blood and lung lavage myeloid cells during the disease trajectories of moderate compared with severe COVID-19 with long-lasting ill-health. Single-cell phenotyping (transcriptome/proteome) will identify innate immune mechanisms determining acute and long-term pathogenesis and resolution. (ii) Ontogeny trajectory modelling of paired blood and lung lavage myeloid cells, in conjunction with epigenetic mapping (scATACseq) of identified pathways, will pinpoint monocyte drivers and biomarkers of acute and long-term pathogenic or resolving lung responses. (iii) An in vitro 2D and 3D model of human lung cell infection with SARS-CoV-2 will test the therapeutic potential of pathogenic and resolving pathways identified above.
Deliverables: Predicative myeloid biomarkers of acute and long-term COVID-19 severity, and therapeutic targets that could restrain aberrant pathogenic responses.
Publications
Alivernini S
(2024)
Using explainable artificial intelligence to predict and forestall flare in rheumatoid arthritis.
in Nature medicine
Clayton SA
(2021)
Inflammation causes remodeling of mitochondrial cytochrome c oxidase mediated by the bifunctional gene C15orf48.
in Science advances
Farina L
(2022)
Pro Nerve Growth Factor and Its Receptor p75NTR Activate Inflammatory Responses in Synovial Fibroblasts: A Novel Targetable Mechanism in Arthritis
in Frontiers in Immunology
Johnson PA
(2023)
Three-dimensional, in-vitro approaches for modelling soft-tissue joint diseases.
in The Lancet. Rheumatology
Kurowska-Stolarska M
(2022)
Synovial tissue macrophages in joint homeostasis, rheumatoid arthritis and disease remission.
in Nature reviews. Rheumatology
MacDonald L
(2021)
COVID-19 and RA share an SPP1 myeloid pathway that drives PD-L1+ neutrophils and CD14+ monocytes.
in JCI insight
Ng MTH
(2024)
A single cell atlas of frozen shoulder capsule identifies features associated with inflammatory fibrosis resolution.
in Nature communications
Paoletti A
(2024)
Liposomal AntagomiR-155-5p Restores Anti-Inflammatory Macrophages and Improves Arthritis in Preclinical Models of Rheumatoid Arthritis.
in Arthritis & rheumatology (Hoboken, N.J.)
Van Gijsel-Bonnello M
(2022)
Salt-inducible kinase 2 regulates fibrosis during bleomycin-induced lung injury.
in The Journal of biological chemistry
Description | We uncovered the stages of macrophage activation driven by SARS-Cov2 infected epithelial cells using established by us 3D co-culture model and patient samples.. We also identified pathways that negatively regulate the development of cytokine storm in patients with mild COVID-19. This includes lambda interferon induced Protein S production by epithelial cells. Infected epithelial cell derived Protein S inhibits the activation of infiltrating pro-inflammatory macrophages and induce their phenotype switch to resolving macrophages in the lung of patients with mild COVID-19 and in co-culture model. In addition, we uncovered the pathogenic macrophage cluster associated with musculoskeletal symptoms of patients with long COVID-19. Since last submission, we uncovered that Protein S is a key pathway that drives regeneration of ciliated bronchial epithelium after viral infections. Simakou et al has been submitted as short report to Experimental Medicine Journal. We identified cellular and molecular mechanisms associated with musculoskeletal symptoms of patients with long COVID19. Data is being prepared for publication |
Exploitation Route | The most important discoveries that could in future inform treatment of patients with long COVID-19 is the discovery of the pathogenic macrophages clusters that are present in the joint of patients suffering joint symptoms in long COVID-19. Discovery of a pathway regenerating epithelium after viral infection could inform future therapies |
Sectors | Healthcare Pharmaceuticals and Medical Biotechnology |
Title | Established human 3D ciliated epithelium, mucus producing cells, basal cells and macrophages resembling interactions between immune cells and lung epithelium during viral infection |
Description | We established bronchial epithelial-immune cell organoid system that allows us to test the regeneration pathways after viral infection. We uncovered novel PROTEIN S driven mechanisms leading to the regeneration of bronchial epithelium after flu and COVID-19 infections. Manuscript led by Simakou et al has been submitted. |
Type Of Material | Model of mechanisms or symptoms - human |
Year Produced | 2024 |
Provided To Others? | No |
Impact | 3D ciliated epithelium, mucus producing cells, basal cells and macrophages system can be used to test pathogenic and resolving pathways operating in bronchial space of the lung by respiratory medeicine researchers. |
Description | synovial inflammation during long COVID-19 |
Organisation | Agostino Gemelli University Polyclinic |
Country | Italy |
Sector | Hospitals |
PI Contribution | Investigation of the cellular and molecular mechanisms of joint pain in patients suffering long COVID-19 using scRNASeq and functional assays |
Collaborator Contribution | recruitment of patients with long COVID-19 and collections of synovial biopsies |
Impact | presentations of discoveries at British Pharmacology Society Meeting September 2021 and EULAR2021 |
Start Year | 2021 |
Description | Invited lecture at British Society of Pharmacology 2021 |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | More than 100 people attend the event, the follow up dicussion indicated an increased interest in common targetable pathogenic mechanisms in lung and synovium |
Year(s) Of Engagement Activity | 2021 |
Description | lay summary presentation of the discovery made on the grant at NRAS meeting (National Rheumatoid Arthritis Society) Scotland |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Patients, carers and/or patient groups |
Results and Impact | Around 100 patients with arthritis attended the event, and PhD students /researchers associated with PI group reported increased interest of Patient Partners group in their work. |
Year(s) Of Engagement Activity | 2021 |